The most common adverse events in the intravenous pediatric study, mostly mild to moderate, were thrombocytopenia, anemia, hypertriglyceridemia, leukopenia, elevated AST and ALT, and hypophosphatemia [25]. This evidence concerns the gene GPT and hypophosphatemia.